Soligenix Inc (SNGX)

$1.18 +0.03 (2.61%)
Market Cap 11.90M
Revenue (ttm) 120,000.00
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,891.67%
Debt to Equity Ratio 0.00
Volume 104,500
Avg Vol 257,750
Day's Range N/A - N/A
Shares Out 10.09M
Stochastic %K 76%
Beta 2.01
Analysts Strong Buy
Price Target $17.50

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 538 8200
Fax: 609 452 6467
Address:
29 Emmons Drive, Suite B-10, Princeton, United States
SaTwits
SaTwits Feb. 28 at 2:17 AM
$SNGX going to buy small on Monday
0 · Reply
PTI127
PTI127 Feb. 27 at 1:59 PM
$APRE this going to be crazy soon @Bhaddar1 like no other strong 💪 team behind it $SNGX $QNCX
0 · Reply
RealTradingFlow
RealTradingFlow Feb. 27 at 1:42 AM
$SNGX had news today, i think market didnt catch on, expect tomrorow to get vol
0 · Reply
durocali
durocali Feb. 26 at 9:54 PM
$SNGX this stock went parabolic up on US FDA orphan designation. i know this is just positive opinion on EU side.. but would be strange to be already priced in the current stock price. Stock did absolutely nothing on this news..
1 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 26 at 3:27 PM
BioMedNewsBreaks — $SNGX Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease https://ibn.fm/tintJ
0 · Reply
focafoca99
focafoca99 Feb. 26 at 2:47 PM
$SNGX positive opinion from EMA, nice!
0 · Reply
Bhaddar1
Bhaddar1 Feb. 26 at 1:16 PM
$SNGX let’s go baby
0 · Reply
YoloAlfred
YoloAlfred Feb. 26 at 12:38 PM
$SNGX added....Bio-tramping
0 · Reply
Troyboy1
Troyboy1 Feb. 26 at 12:37 PM
$SNGX Good news! lets go🕺🙌
0 · Reply
BullButter23
BullButter23 Feb. 26 at 12:34 PM
$SNGX https://newsfilter.io/articles/soligenix-receives-positive-opinion-from-the-european-medicines-agency-on-the-request-for-orphan-dru-2cf9f3d92ebbd80b23d91c561f8cee35
0 · Reply
Latest News on SNGX
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Feb 26, 2026, 7:30 AM EST - 2 days ago

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Soligenix to Present at BIO Investment & Growth Summit

Feb 24, 2026, 7:30 AM EST - 4 days ago

Soligenix to Present at BIO Investment & Growth Summit

Soligenix Details Recent Progress and Upcoming Milestones

Feb 12, 2026, 7:30 AM EST - 16 days ago

Soligenix Details Recent Progress and Upcoming Milestones

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Dec 18, 2025, 7:30 AM EST - 2 months ago

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Dec 17, 2025, 1:23 PM EST - 2 months ago

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 17, 2025, 7:30 AM EST - 2 months ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Dec 3, 2025, 8:30 AM EST - 3 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 19, 2025, 7:30 AM EST - 3 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Nov 7, 2025, 7:30 AM EST - 4 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Oct 14, 2025, 7:30 AM EDT - 4 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Oct 7, 2025, 7:30 AM EDT - 5 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 30, 2025, 7:30 AM EDT - 5 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 29, 2025, 4:05 PM EDT - 5 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 5 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Sep 23, 2025, 7:30 AM EDT - 5 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 4, 2025, 7:30 AM EDT - 6 months ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:30 AM EDT - 6 months ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Why Is Soligenix Stock Soaring On Monday?

Aug 18, 2025, 1:03 PM EDT - 6 months ago

Why Is Soligenix Stock Soaring On Monday?

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 18, 2025, 7:30 AM EDT - 6 months ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Aug 14, 2025, 7:30 AM EDT - 7 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Aug 8, 2025, 8:30 AM EDT - 7 months ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 31, 2025, 7:30 AM EDT - 7 months ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 8, 2025, 7:30 AM EDT - 8 months ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jul 1, 2025, 7:30 AM EDT - 8 months ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Jun 6, 2025, 9:37 AM EDT - 9 months ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 9, 2025, 7:30 AM EDT - 10 months ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Apr 14, 2025, 7:30 AM EDT - 11 months ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Mar 6, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Soligenix to Present at BIO CEO & Investor Conference

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

Soligenix to Present at Upcoming Investor Conferences

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 7, 2024, 7:30 AM EDT - 1 year ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix Announces Partnership with Sterling Pharma Solutions

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 20, 2024, 9:00 AM EDT - 1 year ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 16, 2024, 9:00 AM EDT - 1 year ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AREC

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 15, 2024, 10:16 AM EDT - 1 year ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

SaTwits
SaTwits Feb. 28 at 2:17 AM
$SNGX going to buy small on Monday
0 · Reply
PTI127
PTI127 Feb. 27 at 1:59 PM
$APRE this going to be crazy soon @Bhaddar1 like no other strong 💪 team behind it $SNGX $QNCX
0 · Reply
RealTradingFlow
RealTradingFlow Feb. 27 at 1:42 AM
$SNGX had news today, i think market didnt catch on, expect tomrorow to get vol
0 · Reply
durocali
durocali Feb. 26 at 9:54 PM
$SNGX this stock went parabolic up on US FDA orphan designation. i know this is just positive opinion on EU side.. but would be strange to be already priced in the current stock price. Stock did absolutely nothing on this news..
1 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 26 at 3:27 PM
BioMedNewsBreaks — $SNGX Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease https://ibn.fm/tintJ
0 · Reply
focafoca99
focafoca99 Feb. 26 at 2:47 PM
$SNGX positive opinion from EMA, nice!
0 · Reply
Bhaddar1
Bhaddar1 Feb. 26 at 1:16 PM
$SNGX let’s go baby
0 · Reply
YoloAlfred
YoloAlfred Feb. 26 at 12:38 PM
$SNGX added....Bio-tramping
0 · Reply
Troyboy1
Troyboy1 Feb. 26 at 12:37 PM
$SNGX Good news! lets go🕺🙌
0 · Reply
BullButter23
BullButter23 Feb. 26 at 12:34 PM
$SNGX https://newsfilter.io/articles/soligenix-receives-positive-opinion-from-the-european-medicines-agency-on-the-request-for-orphan-dru-2cf9f3d92ebbd80b23d91c561f8cee35
0 · Reply
Stock_Catcher
Stock_Catcher Feb. 26 at 12:31 PM
$SNGX Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
0 · Reply
Bhaddar1
Bhaddar1 Feb. 25 at 6:49 PM
$APRE $BRTX $MVIS $QNCX $SNGX Slow and steady $APRE WILL GIVE GOOD BOUNCES HERE DUE NOW JUMP BEFORE 300% one day jump coming
0 · Reply
Bhaddar1
Bhaddar1 Feb. 25 at 2:43 PM
$APRE $BRTX $MVIS $QNCX $SNGX
0 · Reply
Farhas80
Farhas80 Feb. 25 at 2:38 PM
$SNGX we might see huge move around march 5th or 6th . Looking for 200 to 300% gain.
2 · Reply
WheresHunter
WheresHunter Feb. 25 at 1:40 PM
$SNGX move please
1 · Reply
Bhaddar1
Bhaddar1 Feb. 25 at 11:27 AM
$APRE $BRTX $MVIS $QNCX $SNGX Told people but don’t listen 👂 🚀🔥💎🔜👀😎
0 · Reply
Bhaddar1
Bhaddar1 Feb. 24 at 9:06 PM
$QNCX we need to see volume here @topstockalerts @StockAuthority at $APRE I REMEMBER IN 2021 I had them probably lost money but time to buy in them $SNGX $MVIS
0 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 24 at 5:16 PM
BioMedNewsBreaks – $SNGX CEO to Present at BIO Investment & Growth Summit https://ibn.fm/ewLbC
0 · Reply
ppl_first
ppl_first Feb. 24 at 4:56 PM
$SNGX Drag: Small oncology niche, long trial timeline. Recovery: Phase 3 data window. High binary asymmetry but timeline heavy.
0 · Reply
Bhaddar1
Bhaddar1 Feb. 24 at 2:34 PM
$BRTX $QNCX $APRE $SNGX $MVIS BIGGER MOVE AHEAD HERE BUY AND HOLD AND WAIT FOR TURN
0 · Reply
CoffeeRocks
CoffeeRocks Feb. 24 at 1:23 AM
$BHAT $XTKG $SNGX BHAT best one here GOLDEN 🐉 Waiting On 📰 .20 offering To fill Easy .20-.25
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 7:04 PM
$SNGX RSI: 34.78, MACD: -0.0712 Vol: 0.10, MA20: 1.17, MA50: 1.31 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply